Ariad Pharmaceuticals, Inc.  

(Public, NASDAQ:ARIA)   Watch this stock  
Find more results forARIA
8.21
+0.18 (2.24%)
May 27 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 7.96 - 8.22
52 week 4.37 - 10.07
Open 8.06
Vol / Avg. 2.61M/3.80M
Mkt cap 1,605.20M
P/E     -
Div/yield     -
EPS -1.23
Shares 191.23M
Beta 1.73
Inst. own 74%
Aug 3, 2016
Q2 2016 ARIAD Pharmaceuticals Inc Earnings Release (Estimated) - 9:30am GMT-4 - Add to calendar
Jul 22, 2016
ARIAD Pharmaceuticals Inc Annual Shareholders Meeting (Estimated) - 10:00am GMT-4 - Add to calendar
Jun 17, 2016
ARIAD Pharmaceuticals Inc Analyst and Investor Day Add to calendar
Jun 6, 2016
ARIAD Pharmaceuticals Investor and Analyst Briefing and Webcast - 8:00am GMT-4 - Add to calendar
May 10, 2016
Q1 2016 ARIAD Pharmaceuticals Inc Earnings Release
May 10, 2016
Q1 2016 ARIAD Pharmaceuticals Inc Earnings Call - Webcast
May 9, 2016
ARIAD Pharmaceuticals Inc & Incyte Corp Announce Agreement for Incyte to Acquire ARIAD's European Operations and In-license Iclusig (ponatinib) in Europe Call - Webcast
Mar 17, 2016
ARIAD Pharmaceuticals Inc at Barclays Global Healthcare Conference - Webcast
Mar 9, 2016
ARIAD Pharmaceuticals Inc at Cowen Health Care Conference
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '16) 2015
Net profit margin -151.10% -194.57%
Operating margin -134.46% -182.89%
EBITD margin - -172.15%
Return on average assets -41.12% -40.21%
Return on average equity - -
Employees 459 -
CDP Score - -

Address

26 LANDSDOWNE ST
CAMBRIDGE, MA 2139
United States - Map
+1-617-4940400 (Phone)
+1-617-4948144 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

ARIAD Pharmaceuticals, Inc. (ARIAD) is an oncology company. The Company is focused on transforming the lives of cancer patients with medicines. The Company's product pipeline includes Iclusig (ponatinib), brigatinib, AP32788 and ridaforolimus. The Company's Iclusig is a tyrosine kinase inhibitor (TKI) that is approved in the United States, the European Union, Australia, Switzerland, Israel and Canada for the treatment of adult patients with chronic myeloid leukemia (CML), and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). Its Brigatinib is an investigational inhibitor of anaplastic lymphoma kinase (ALK). Its AP32788 is a TKI, which is designed as a targeted therapy for patients with non-small cell lung cancer (NSCLC) with specific mutations in two kinases, epidermal growth factor receptor (EGFR), or human epidermal growth factor receptor 2 (HER2). Its Ridaforolimus is an investigational inhibitor of the mammalian target of rapamycin (mTOR).

Officers and directors

Alexander J. Denner Ph.D. Independent Chairman of the Board
Age: 46
Bio & Compensation  - Reuters
Paris Panayiotopoulos President, Chief Executive Officer, Director
Age: 41
Bio & Compensation  - Reuters
Manmeet S. Soni Chief Financial Officer, Executive Vice President, Treasurer
Age: 38
Bio & Compensation  - Reuters
Thomas J DesRosier J.D. Executive Vice President, Chief Legal and Administrative Officer, Secretary
Age: 60
Bio & Compensation  - Reuters
Martin J. Duvall Executive Vice President, Chief Commercial Officer
Age: 53
Bio & Compensation  - Reuters
Maria E. Cantor Senior Vice President - Corporate Affairs
Age: 47
Bio & Compensation  - Reuters
Daniel M. Bollag Ph.D. Senior Vice President - Regulatory Affairs and Quality
Age: 54
Bio & Compensation  - Reuters
Hugh M. Cole Senior Vice President, Chief Business Officer
Age: 50
Bio & Compensation  - Reuters
Frank G. Haluska M.D., Ph.D. Senior Vice President - Clinical Research and Development and Chief Medical Officer
Age: 56
Bio & Compensation  - Reuters
Timothy P. Clackson Ph.D. President - Research and Development, Chief Scientific Officer
Age: 50
Bio & Compensation  - Reuters